Cytosorbents targets operating cash flow breakeven in 2H 2026 while planning DrugSorb-ATR de novo submission in late 2026/early 2027 (NASDAQ:CTSO)
· seekingalpha.com
Cytosorbents (CTSO) Q1 2026 earnings call recap: revenue, margins, cash burn, and FDA DrugSorb-ATR delay plus DOAC upside.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...